Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479448 | 1.00 | EGLN2 (0.32) | EGLN2NR1H2NR1H3CRHR1MAPT | |
| SCHEMBL3223842 | 1.00 | EGLN2 (0.32) | EGLN2NR1H2NR1H3CRHR1MAPT | |
| Hydrochloric Acid SCHEMBL4491883 | 0.99 | EGLN2 (0.32) | EGLN2NR1H2NR1H3CRHR1MAPT | |
| Hydrochloric Acid SCHEMBL4491882 | 0.98 | EGLN2 (0.31) | EGLN2NR1H2NR1H3CRHR1 | |
| SCHEMBL4479995 | 0.97 | EGLN2 (0.32) | EGLN2NR1H2NR1H3CRHR1MAPT | |
| SCHEMBL4480455 | 0.97 | EGLN2 (0.32) | EGLN2NR1H2NR1H3CRHR1MAPT | |
| SCHEMBL4484155 | 0.97 | EGLN2 (0.32) | EGLN2NR1H2NR1H3CRHR1MAPT | |
| SCHEMBL4472793 | 0.96 | EGLN2 (0.36) | EGLN2CRHR1MAPTMBOAT4ALDH1A1 | |
| SCHEMBL4488076 | 0.96 | EGLN2 (0.36) | EGLN2CRHR1MAPTMBOAT4ALDH1A1 | |
| SCHEMBL4492532 | 0.96 | EGLN2 (0.36) | EGLN2CRHR1MAPTMBOAT4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903436-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | UNIV PENNSYLVANIA (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-2903436-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | UNIV PENNSYLVANIA (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-3219207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | The Trustees Of The University Of Pennsylvania (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2017-06-22 | — | — | US | disclosed |
| US-9649317-B2 | Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2015-08-13 | — | — | US | disclosed |
| US-20100056371-A1 | Use of Azolopyrimidines for Controlling Phytopathogenic Harmful Fungi | BASF SE (DE) | 2010-03-04 | — | — | US | disclosed |
| US-7507739-B2 | 6-[(substituted)phenyl]triazolopyrimidines as anticancer agents | WYETH (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1680425-B1 | 6- [(SUBSTITUTED)PHENYL] TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH CORP (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1680425-A1 | 6- [(SUBSTITUTED)PHENYL] TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | Wyeth Holdings Corporation (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20050090508-A1 | 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents | WYETH HOLDINGS CORPORATION (US) | 2005-04-28 | — | — | US | disclosed |
| WO-2005030775-A1 | 6-[(SUBSTITUTED)PHENYL]TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, PRNP, PSEN2 | EGLN2 4324/4885NR1H2 3224/4885NR1H3 4033/4885 |
| US-20100056371-A1 | Use of Azolopyrimidines for Controlling Phytopathogenic Harmful Fungi | DPM1, TYMP, G6PD | EGLN2 2270/4885NR1H2 4009/4885NR1H3 4395/4885 |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, SYNJ1, PARK7 | EGLN2 4880/4885NR1H2 4295/4885NR1H3 4664/4885 |
| US-20050090508-A1 | 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents | ABCC1, ABCB1, TUBB6 | EGLN2 3675/4885NR1H2 3315/4885NR1H3 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.